These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11231342)

  • 1. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease.
    Garber SL; Mirochnik Y; Brecklin CS; Unemori EN; Singh AK; Slobodskoy L; Grove BH; Arruda JA; Dunea G
    Kidney Int; 2001 Mar; 59(3):876-82. PubMed ID: 11231342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition reduces the effect of bromoethylamine-induced papillary necrosis and renal fibrosis.
    Garber SL; Mirochnik Y; Desai SS; Arruda JA; Dunea G
    J Am Soc Nephrol; 1998 Jun; 9(6):1052-9. PubMed ID: 9621288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in collagenases and TGF-beta precede structural alterations in a model of chronic renal fibrosis.
    Mo W; Brecklin C; Garber SL; Song RH; Pegoraro AA; Au J; Arruda JA; Dunea G; Singh AK
    Kidney Int; 1999 Jul; 56(1):145-53. PubMed ID: 10411687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of experimentally induced papillary necrosis to focal segmental glomerulosclerosis and nephrotic proteinuria.
    Garber SL; Mirochnik Y; Arruda JA; Dunea G
    Am J Kidney Dis; 1999 Jun; 33(6):1033-9. PubMed ID: 10352190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relaxin and the progression of kidney disease.
    Samuel CS; Hewitson TD
    Curr Opin Nephrol Hypertens; 2009 Jan; 18(1):9-14. PubMed ID: 19077683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxin in cardiovascular and renal disease.
    Samuel CS; Hewitson TD
    Kidney Int; 2006 May; 69(9):1498-502. PubMed ID: 16672919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxin regulates collagen overproduction associated with experimental progressive renal fibrosis.
    Samuel CS; Mookerjee I; Masterson R; Tregear GW; Hewitson TD
    Ann N Y Acad Sci; 2005 May; 1041():182-4. PubMed ID: 15956704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis.
    Hewitson TD; Ho WY; Samuel CS
    Endocrinology; 2010 Oct; 151(10):4938-48. PubMed ID: 20826562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function.
    Morrissey J; Hruska K; Guo G; Wang S; Chen Q; Klahr S
    J Am Soc Nephrol; 2002 Jan; 13 Suppl 1():S14-21. PubMed ID: 11792757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of relaxin in two models of renal mass reduction.
    Garber SL; Mirochnik Y; Brecklin C; Slobodskoy L; Arruda JA; Dunea G
    Am J Nephrol; 2003; 23(1):8-12. PubMed ID: 12373075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis.
    Hewitson TD; Mookerjee I; Masterson R; Zhao C; Tregear GW; Becker GJ; Samuel CS
    Endocrinology; 2007 Feb; 148(2):660-9. PubMed ID: 17095590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bromoethylamine hydrobromide on systemic acid-base balance.
    Nakamura Y; Sasaki S; Shigai T; Marumo F
    Tohoku J Exp Med; 1988 Sep; 156(1):23-32. PubMed ID: 3194903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
    Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
    Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.
    Ma LJ; Nakamura S; Whitsitt JS; Marcantoni C; Davidson JM; Fogo AB
    Kidney Int; 2000 Dec; 58(6):2425-36. PubMed ID: 11115076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relaxin: an endogenous renoprotective factor?
    Hewitson TD; Samuel CS
    Ann N Y Acad Sci; 2009 Apr; 1160():289-93. PubMed ID: 19416206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat.
    Chen CO; Park MH; Forbes MS; Thornhill BA; Kiley SC; Yoo KH; Chevalier RL
    Am J Physiol Renal Physiol; 2007 Mar; 292(3):F946-55. PubMed ID: 17107943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic unilateral ureteral obstruction is associated with interstitial fibrosis and tubular expression of transforming growth factor-beta.
    Wright EJ; McCaffrey TA; Robertson AP; Vaughan ED; Felsen D
    Lab Invest; 1996 Feb; 74(2):528-37. PubMed ID: 8780170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.
    Samuel CS; Zhao C; Bond CP; Hewitson TD; Amento EP; Summers RJ
    Kidney Int; 2004 Jun; 65(6):2054-64. PubMed ID: 15149318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance microscopy of toxic renal injury induced by bromoethylamine in rats.
    Hedlund LW; Maronpot RR; Johnson GA; Cofer GP; Mills GI; Wheeler CT
    Fundam Appl Toxicol; 1991 May; 16(4):787-97. PubMed ID: 1884916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.
    Negri AL
    J Nephrol; 2004; 17(4):496-503. PubMed ID: 15372410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.